Abstracts tagged "Biologicals"

Abstract Number: L12 • ACR Convergence 2021
Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial on Arthritis, Dactylitis, Enthesitis, Psoriasis, QoL and Function
Michaela Koehm¹, Tanja Rossmanith², Ann Christina Foldenauer², Eva Herrmann³, Herbert Kellner⁴, Uta Kiltz⁵, Jürgen Rech⁶, Gerd Burmester⁷, David Kofler⁸, Jan Brandt-Jürgens⁹, Christin Jonetzko¹⁰, Harald Burkhardt¹ and Frank Behrens¹, ¹Rheumatology Goethe-University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ³Institute for Biostatistics and Mathematical Modeling, Goethe-Universität Frankfurt, Frankfurt, Germany, ⁴Praxis Prof. Dr. Kellner, München, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054,, Erlangen, Germany, ⁷Charite Universitaetsmedizin Berlin, Germany and DRFZ, Berlin, Germany, ⁸Universitätsklinikum Köln, Med. Klinik I f. Innere Medizin Immunologische Ambulanz, Köln, Germany, ⁹Rheumatologische Schwerpunktpraxis im Ärztehaus am Walter-Schreiber-Platz, Berlin, Germany, ¹⁰Fraunhofer Insitute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany
Background/Purpose: Methotrexate (MTX) is often used as first-line DMARD-therapy in active psoriatic arthritis (PsA). Randomized clinical trials usually require treatment failure or intolerance of csDMARD/MTX…
Abstract Number: L18 • ACR Convergence 2021
Humoral and Cellular Immune Responses to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Cohort Study
Satveer K Mahil¹, Katie Bechman², Antony Raharja¹, Clara Domingo-Vila³, David Baudry¹, Matt Brown², Andrew Cope², Tejus Dasandi¹, Hataf Khan⁴, Thomas Lechmere⁴, Michael Malim⁴, Freya Meynell¹, Emily Pollock³, Kamila Sychowska³, Jonathan Barker¹, Sam Norton⁵, James Galloway², Katie Doores⁴, Timothy Tree³ and Catherine Smith¹, ¹St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, ²Centre for Rheumatic Diseases, King's College London, London, ³Department of Immunobiology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom, ⁴Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom, ⁵Psychology Department, Institute for Psychiatry Psychology & Neuroscience, King’s College London, London
Background/Purpose: COVID-19 vaccines have robust immunogenicity in the general population. Data on individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains limited. Our cohort…
Abstract Number: L19 • ACR Convergence 2021
Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial
Nils Venhoff¹, Wolfgang Schmidt², Raoul Bergner³, Jürgen Rech⁴, Leonore Unger⁵, Hans-Peter Tony⁶, Meryl Mendelson⁷, Christian Sieder⁸, Meron Maricos⁸ and Jens Thiel⁹, ¹Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany, ²Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Lindenberger Weg 19, 13125 Berlin, Germany, Berlin, Germany, ³Medizinische Klinik A, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany, ⁴Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054,, Erlangen, Germany, ⁵Medical Department 1, Städtisches Klinikum Dresden, Dresden, Germany, ⁶Department of Medicine 2, Rheumatology and Clinical Immunology Oberduerrbachertstr. 697080, Wuerzburg, Germany, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma GmbH, Nuremberg, Germany, ⁹Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany; Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Background/Purpose: Little is known about glucocorticoid-sparing agents in giant cell arteritis (GCA) except for IL-6 inhibition. Secukinumab (SEC) has shown significant improvements in the signs…
Abstract Number: 1354 • ACR Convergence 2021
Differences in Real-World Patient Characteristics of 8921 Patients with Psoriasis with and Without Comorbid Psoriatic Arthritis Using the UK BADBIR Database
William Tillett¹, Alexis Ogdie², Patricia Gorecki³ and Alun Passey⁴, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University of Pennsylvania, Philadelphia, PA, ³Janssen Medical Affairs, London, United Kingdom, ⁴Janssen Real World Evidence, HEMAR EMEA, High Wycombe, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis (PsO) and multiple comorbidities.1 Approximately one-third of patients with PsO develop PsA during…
Abstract Number: 1565 • ACR Convergence 2021
Causal Mediation Analysis of the Relationship of Canakinumab’s Protective Effect Against Gout Flares and High-sensitivity C-reactive Protein in the CANTOS Trial
Kazuki Yoshida¹, Robert J. Glynn¹, Hyon K. Choi², Brendan M. Everett¹, Yi Li³, Jean G. MacFadyen¹, Paul M. Ridker¹ and DH Solomon¹, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Lexington, MA, ³Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Previous analyses in the CANTOS trial demonstrated a benefit of canakinumab (CAN; IL-1β inhibitor) on gout flares. We aimed to quantify the mediating role…
Abstract Number: 1761 • ACR Convergence 2021
Comparison of Belimumab and Standard of Care by Inverse Probability of Treatment Weighting Analyses Based on Propensity Score in Patients with Systemic Lupus Erythematosus in the Maintenance Phase
yusuke Miyazaki¹, Shingo Nakayamada¹, Shigeru Iwata¹, Kentaro Hanami¹, Shunsuke Fukuyo¹, Koshiro Sonomoto¹, Akio Kawabe¹, Yoshino Inoue¹, Naoaki Okubo¹ and Yoshiya Tanaka², ¹The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyusyu, Fukuoka, Japan, ²University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Development of molecular-targeted agents is essential in treat-to-target treatment strategies for systemic lupus erythematosus (SLE). We analyzed the efficacy and safety of belimumab (BEL)…
Abstract Number: 1944 • ACR Convergence 2021
Sustained Remission/Low Disease Activity Is Feasible in the Long Term in Patients with Psoriatic Arthritis Treated with IL-23/12 Inhibition with Ustekinumab (STELARA®) and Tumor Necrosis Factor Inhibitors in a Real-World, Multicenter Study
Josef Smolen¹, Paul Bergmans², Kurt de Vlam³, Elisa Gremese⁴, Beatriz Joven-Ibáñez⁵, Tatiana Korotaeva⁶, Wim Noël⁷, Michael Nurmohamed⁸, Petros Sfikakis⁹, Stefan Siebert¹⁰, Elke Theander¹¹ and Laure Gossec¹², ¹Medical University of Vienna, Vienna, Austria, ²Janssen-Cilag BV, Breda, Netherlands, ³University Hospitals Leuven, Leuven, Belgium, ⁴Fondazione Policlinico A Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁵University Hospital 12 de Octubre, Madrid, Spain, ⁶VA Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁷Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, ⁸Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ⁹National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹Janssen Cilag, Lund, Sweden, ¹²Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France
Background/Purpose: Among treatment options for PsA, IL-23/12 inhibition with ustekinumab (UST) was the first new biologic after TNF inhibitors (TNFi). Few data compare long-term effectiveness…
Abstract Number: 0201 • ACR Convergence 2021
Australian Psoriatic Arthritis (PsA) Biologic Disease-modifying Antirheumatic Drug (bDMARD) Treatment Pathways Using Sankey Diagrams and Predictive Analysis: A Combined Australian Rheumatology Association Database (ARAD) and Pharmaceutical Benefits Scheme (PBS) Analysis
Ashley Fletcher¹, Lyn March², Marissa Lassere³, Catherine Hill⁴, Claire Barrett⁵, Graeme Carroll⁶, Premarani Sinnathurai⁷ and Rachelle Buchbinder⁸, ¹Cabrini Health, Malvern, Australia, ²Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Sydney, Australia, ³St George Hospital; School of Population Health, University of New South Wales, Carlton, Australia, ⁴Queen Elizabeth Hospital, Woodville, Australia, ⁵Redcliffe Hospital, University of Queensland, Margate Beach, Australia, ⁶Fiona Stanley Hospital, Perth, Australia, ⁷Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, Sydney, Australia, ⁸Cabrini Health/Monash University, Malvern, Australia
Background/Purpose: To describe current bDMARD treatment patterns for ARAD participants with PsA, after combining with linked government PBS data.Methods: ARAD, a voluntary longitudinal observational database…
Abstract Number: 0835 • ACR Convergence 2021
Immunogenicity of Rituximab Biosimilar GP2013 in Chronic Inflammatory Rheumatic Disorders in Daily Clinical Practice
Jerome Avouac¹, Rodolphe Cougnaud-Murail¹, Claire Goulvestre², Sophie Dumas³, Anna Molto⁴, Corinne Miceli-Richard⁵, ornella conort³, Frederic Batteux² and Yannick Allanore¹, ¹Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France, ²Université de Paris, Service d'Immunologie, Hôpital Cochin, AP-HP.CUP, Paris, France, ³Université de Paris, Service de pharmacie, Hôpital Cochin, AP-HP.CUP, Paris, France, ⁴Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ⁵Assistance Publique Hpitaux de PAris, Paris, France
Background/Purpose: To study in daily practice the risk of immunogenicity of patients treated with rituximab (RTX) biosimilar GP2013 for their chronic inflammatory rheumatic disorder.Methods: A…
Abstract Number: 1232 • ACR Convergence 2021
Synovial Tissue Lymphoid Aggregates Are Associated with Response to Rituximab Therapy in Rheumatoid Arthritis Patients
Matthew Turk¹, Candice Low², Carl Orr³, Richard Conway⁴, Kieran Murray⁵, Ursula Fearon⁶ and Douglas Veale⁷, ¹St. Vincents University Hospital, Dublin, Ireland, ²St. Vincent's University Hospital, Dublin, Ireland, ³St Vincent's Hospital, Dublin, Ireland, ⁴St. James's University Hospital, Dublin, Ireland, ⁵Saint Vincent's University Hospital, Dublin, Ireland, ⁶Trinity College Dublin, Dublin, Ireland, ⁷University College Dublin, Dublin, Ireland
Background/Purpose: Activated B lymphocytes and plasma cells are implicated in the pathogenesis of rheumatoid arthritis (RA). The anti-CD20 monoclonal antibody therapy (Rituximab) is an effective…
Abstract Number: 1355 • ACR Convergence 2021
Psoriatic Arthritis Incidence Among Patients Receiving Biologic Medications for Psoriasis; A Nested Case Control Study
Iftach Sagy¹, Yael Shalev Rosenthal², Naama Schwartz² and Lev Pavlovsky², ¹Clinical Research Center, Soroka University Medical Center, Beer Sheva and Ben Gurion University of the Negev, DVIRA, Israel, ²Rabin Medical Center, Petach Tikva, Israel
Background/Purpose: The objective of this study was to investigate the effect of biological treatments for psoriasis on the incidence of psoriatic arthritis.Methods: A retrospective cohort…
Abstract Number: 1629 • ACR Convergence 2021
Effect of Drug Withdrawal on Interleukin-1 or Interleukin-6 Inhibitor Associated Diffuse Lung Disease
Vivian Saper¹, Sampath Prahalad², Scott Canna³, Rabheh Abdul-Aziz⁴, Marcela Alvarez⁵, Catherine Bingham⁶, Brigitte Bader-Meunier⁷, Imelda Balboni⁸, Roberta Berard⁹, Roxana Bolaria¹⁰, Alexis Boneparth¹¹, Alicia Casey¹², Elaine Cassidy¹³, Joyce C. Chang¹⁴, Michal Cidon¹⁵, Kathleen Collins¹⁶, Aileen M. Dickenson¹⁷, Graciela Espada⁵, Martha Fishman¹², Elaine Flanagan¹⁸, Timothy Hahn¹⁹, Ankur K. Jindal²⁰, Ozgur Kasapcopur²¹, Marisa Klein-Gitelman²², Timothy Klouda¹², Mikhail Kostik²³, Carol Lake²⁴, Mariana Marques²⁵, Michael Ombrello²⁶, Karen Onel²⁷, Omkar Phadke²⁸, Angelo Ravelli²⁹, Adam Reinhardt³⁰, Amanda D. Robinson³¹, Kelly Rouster-Stevens³², Nadine Saad²⁷, Grant Schulert³³, Susan Shenoi³⁴, Cory Stingl¹⁴, Anjali Sura³⁵, Melissa Tesher³⁶, Jessica Tibaldi³⁷, Kathryn Torok³⁸, Cathy Tsin³⁹, Natalia Vasquez-Canizares⁴⁰, D. Sofia Villacis-Nunez⁴¹, Ben Whitehead⁴², Holly Wobma¹², Lawrence Zemel⁴³ and Elizabeth Mellins¹, ¹Stanford University, Stanford, CA, ²Emory + Children's Pediatric Institute, Atlanta, GA, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴University at Buffalo, Buffalo, NY, ⁵Hospital de Niños Dr Ricardo Gutierrez, Buenos Aires, Argentina, ⁶Penn State Children's Hospital, Allentown, PA, ⁷Pediatric Immuno-hematology, Necker Hospital, APHP, Paris, France, ⁸Stanford University, Palo Alto, CA, ⁹London Health Sciences Centre, London, ON, Canada, ¹⁰Self, Victoria, BC, Canada, ¹¹Columbia University Medical Center, New York, NY, ¹²Boston Children's Hospital, Boston, MA, ¹³University of Pittsburgh Medical Center Medical Education, Pittsburgh, PA, ¹⁴Children's Hospital of Phildelphia, Philadelphia, PA, ¹⁵Children's Hospital Los Angeles, Los Angeles, CA, ¹⁶LeBonheur Children's Hospital, Memphis, TN, ¹⁷Children's Hospital of Los Angeles, Los Angeles, CA, ¹⁸Emory University and Children's Healthcare of Atlanta, Atlanta, GA, ¹⁹Penn State Childrens Hospital, Hershey, PA, ²⁰Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, İstanbul, Turkey, ²²Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²³Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²⁴National Institutes of Health, Gaithersburg, MD, ²⁵UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, ²⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²⁷Hospital for Special Surgery, New York, NY, ²⁸EMORY, Atlanta, GA, ²⁹Istituto Giannina Gaslini, Genoa, Italy, ³⁰Boys Town National Research Hospital, Omaha, NE, ³¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ³²Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ³³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³⁴Seattle Children's Hospital, Seattle, WA, ³⁵SUNY Upstate Medical University, Syracuse, NY, ³⁶University of Chicago, Chicago, IL, ³⁷IRCSS Istituto G. Gaslini University of Genoa, Genoa, Italy, ³⁸University of Pittsburgh, Pittsburgh, PA, ³⁹Stanford University, Stanford, ⁴⁰Children's Hospital at Montefiore, Bronx, NY, ⁴¹Children's Healthcare of Atlanta - Emory University, Atlanta, GA, ⁴²Queensland Children's Hospital, Brisbane, Australia, ⁴³CCMC, Hartford, CT
Background/Purpose: Severe delayed hypersensitivity reactions (DHR) are under-recognized in inflammatory conditions, particularly drug reaction with eosinophilia and systemic symptoms (DRESS). Previous work has shown this…
Abstract Number: 1773 • ACR Convergence 2021
Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from DISCOVER 1&2 and PSUMMIT Trials
Joris Diels¹, Pushpike Thilakarathne², Agata Schubert³, Fareen Hassan⁴, Steven Peterson⁵ and Wim Noël¹, ¹Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, ²JanssenCilag Ltd, HEMAR Department, Beerse, Belgium, ³Janssen-Cilag Poland, HEMAR Department, Warsaw, Poland, ⁴Janssen-Cilag Ltd, HEMAR Department, High Wycombe, United Kingdom, ⁵Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ
Background/Purpose: Guselkumab is an anti-interleukin (IL)-23 monoclonal antibody recently approved for the treatment of psoriatic arthritis (PsA). In two large Phase III trials of patients…
Abstract Number: 0209 • ACR Convergence 2021
IgG4 Related Disease: Response to Immunosuppressive Therapy – A Single Centre Retrospective Study in the United Kingdom
Shirish Sangle¹, Neil Morton², Alina Casian², Louise Nel², Jennifer Hannah³ and David D'Cruz⁴, ¹Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom, ²Guys and St Thomas' NHS Trust, London, United Kingdom, ³Kings College Hospital, London, United Kingdom, ⁴Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Background/Purpose: IgG4 related disease (IgG4-RD) is a rare immune-mediated condition, increasingly being recognised as a multi-organ disorder. It is a relatively new entity and the…
Abstract Number: 0840 • ACR Convergence 2021
Modelling of Disease Activity in Patients with Inflammatory Arthropathies Treated with Etanercept Originator or Biosimilar as First-Line Biologic: A Real-World Observational Study Using the OPAL Dataset
Claire Deakin¹, Geoffrey Littlejohn², Hedley Griffiths³, Tegan Smith⁴, Catherine OSullivan⁵ and Paul Bird⁶, ¹OPAL Rheumatology Ltd, Sydney, Australia, ²Monash University, Melbourne, Australia, ³Barwon Rheumatology Service, Geelong, Australia, ⁴OPAL Rheumatology Ltd, Kogarah, Australia, ⁵OPAL Rheumatology Ltd, Queenscliff, Australia, ⁶University of New South Wales, Sydney, Australia
Background/Purpose: The availability of biosimilars as non-proprietary versions of established biologic disease-modifying anti-rheumatic drugs (bDMARDs) has increased around the world. Since April 2017 both the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].